Bioceres Crop Solutions Corp.

DB:0G4 Stock Report

Market Cap: €370.0m

Bioceres Crop Solutions Valuation

Is 0G4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0G4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0G4 (€5.95) is trading above our estimate of fair value (€3.51)

Significantly Below Fair Value: 0G4 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0G4?

Key metric: As 0G4 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0G4. This is calculated by dividing 0G4's market cap by their current revenue.
What is 0G4's PS Ratio?
PS Ratio0.9x
SalesUS$441.23m
Market CapUS$385.26m

Price to Sales Ratio vs Peers

How does 0G4's PS Ratio compare to its peers?

The above table shows the PS ratio for 0G4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
SDF K+S
0.5x0.4%€2.0b
SIM0 SIMONA
0.6xn/a€357.0m
ACT AlzChem Group
1.1x7.5%€606.5m
UZU Uzin Utz
0.5x4.3%€250.2m
0G4 Bioceres Crop Solutions
0.9x9.6%€385.3m

Price-To-Sales vs Peers: 0G4 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does 0G4's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HRA H&R GmbH KGaA
0.1x3.0%US$132.56m
NSAK OTI Greentech
0.03xn/aUS$594.62k
B7Y Byotrol
0.04xn/aUS$246.97k
No more companies available in this PS range
0G4 0.9xIndustry Avg. 1.0xNo. of Companies4PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0G4 is good value based on its Price-To-Sales Ratio (0.9x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is 0G4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0G4 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: 0G4 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0G4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.95
€11.44
+92.3%
12.5%€12.27€8.97n/a4
Nov ’25€6.00
€11.47
+91.1%
9.7%€12.02€9.25n/a5
Oct ’25€6.95
€12.25
+76.3%
9.4%€14.52€11.35n/a5
Sep ’25€9.65
€17.47
+81.0%
18.8%€22.98€13.79n/a5
Aug ’25€10.10
€17.47
+72.9%
18.8%€22.98€13.79n/a5
Jul ’25€10.20
€18.61
+82.4%
15.4%€22.98€15.62n/a4
Jun ’25€10.30
€18.61
+80.7%
15.4%€22.98€15.62n/a4
May ’25€11.00
€18.58
+68.9%
15.4%€22.94€15.60n/a4
Apr ’25€11.30
€18.58
+64.5%
15.4%€22.94€15.60n/a4
Mar ’25€11.90
€18.91
+58.9%
13.7%€23.18€15.76n/a5
Feb ’25€12.10
€19.49
+61.1%
22.2%€25.74€13.79n/a5
Jan ’25€11.90
€19.49
+63.8%
22.2%€25.74€13.79n/a5
Dec ’24€10.70
€19.49
+82.1%
22.2%€25.74€13.79n/a5
Nov ’24€10.20
€20.91
+105.0%
20.1%€26.50€14.19€6.005
Oct ’24€10.40
€22.65
+117.8%
22.4%€28.89€13.98€6.955
Sep ’24€11.10
€23.06
+107.8%
23.4%€28.26€13.67€9.655
Aug ’24€11.20
€23.06
+105.9%
23.4%€28.26€13.67€10.105
Jul ’24€12.00
€23.06
+92.2%
23.4%€28.26€13.67€10.205
Jun ’24€10.70
€23.06
+115.5%
23.4%€28.26€13.67€10.305
May ’24€9.50
€23.06
+142.7%
23.4%€28.26€13.67€11.005
Apr ’24€10.20
€25.20
+147.0%
12.5%€28.88€20.96€11.305
Mar ’24€10.40
€25.20
+142.3%
12.5%€28.88€20.96€11.905
Feb ’24€11.00
€25.95
+135.9%
10.7%€29.43€22.07€12.105
Jan ’24€11.00
€25.95
+135.9%
10.7%€29.43€22.07€11.905
Dec ’23€12.70
€25.95
+104.3%
10.7%€29.43€22.07€10.705
Nov ’23€13.90
€25.97
+86.8%
8.8%€28.57€22.96€10.205

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Stanmore Resources

AU$2.8b

Engages in the exploration, development, production, and sale of metallurgical coal in Australia.

S0D

AU$1.91

7D

4.9%

1Y

-15.5%

Tokuyama

JP¥196.7b

Produces and sells various chemical products in Japan.

TBT

JP¥16.60

7D

5.7%

1Y

14.5%

Arkema

€5.7b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€74.55

7D

-4.4%

1Y

-19.9%